Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus
about
VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cellsAnti-angiogenic gene therapy in the treatment of malignant gliomasEvaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies.Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma.Designing Herpes Viruses as Oncolytics.Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapyThe Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor MicroenvironmentCombinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapyCopper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSVMedroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection.Strategies in gene therapy for glioblastoma.The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.Extracellular vesicles and their convergence with viral pathways.Clinical trials of viral therapy for malignant gliomas.Adhesion molecules and the extracellular matrix as drug targets for glioma.Oncolytic Virotherapy: A Contest between Apples and Oranges.Glioma cells promote the expression of vascular cell adhesion molecule-1 on bone marrow-derived mesenchymal stem cells: a possible mechanism for their tropism toward gliomas.BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy.Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.Effects of CCN1 and Macrophage Content on Glioma Virotherapy: A Mathematical Model.Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy.
P2860
Q24618562-B0CEACD3-D1CC-490F-84F1-9A42E85E661BQ26866276-9B72B8A5-6CF0-4A4C-9D12-3F3EA378CA2CQ33720628-7902B39D-EDFA-456A-9CB5-AE207CE6721FQ34045104-FCBB0183-4E9C-4D79-8F4E-9836927DA5E3Q34715771-1514AACB-A983-42B2-A65C-A44B25F95188Q34978311-245C2385-FD25-4B6D-A653-E7634C2A6D49Q36004674-E86D99A0-1950-402B-8D97-41D0EA371BC8Q36142487-3EB4E3A4-0C0F-42A2-A302-BE6C63385DEBQ36644898-3928F7E3-C8C8-4867-8649-6F9BD29289A6Q36658280-F7329B80-DCD2-41C0-A1B1-D6AD3D731B0CQ36849213-34DBCB21-188C-4294-AF2D-20149BBB5662Q36887446-EF88C7D2-89B3-4216-AEAD-280FA6AE9184Q37104963-F8E1CBB8-D3AD-437A-AAF5-A4CA83C4C48FQ37199661-155CA754-ABEA-4EA0-8935-0208B0339272Q37280240-C431A6B9-2017-4FE6-AF58-A501C3E5B1D8Q37420576-D3DC4436-046C-45CD-A600-8AAB0DCC4B30Q37459624-04D894C0-5387-494E-A000-466C52DF1487Q38034222-02DD288D-CEAE-495A-B90B-A99F90C582CEQ38153777-8ECB4522-7533-4AC7-B496-F7DF8FAB20D9Q38780522-ABD575B7-D022-4474-89C3-FA8B25871191Q39230055-83BFEAA3-1D40-41FB-84DE-AC3230A320A9Q39352864-AD05E516-A216-40FB-BB77-873DB69BFD25Q40449206-307B5F55-8106-4C10-8D34-797C90E52A52Q40498974-7402CFC2-0E2B-445B-B22C-E3E832249621Q42155868-A592290E-DBA0-479B-974C-38AB69D50A6BQ52312118-70726C6A-01C7-47F3-AD58-593E20287631
P2860
Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Antitumor efficacy of 34.5ENVE ...... 20"-expressing oncolytic virus
@ast
Antitumor efficacy of 34.5ENVE ...... 20"-expressing oncolytic virus
@en
type
label
Antitumor efficacy of 34.5ENVE ...... 20"-expressing oncolytic virus
@ast
Antitumor efficacy of 34.5ENVE ...... 20"-expressing oncolytic virus
@en
prefLabel
Antitumor efficacy of 34.5ENVE ...... 20"-expressing oncolytic virus
@ast
Antitumor efficacy of 34.5ENVE ...... 20"-expressing oncolytic virus
@en
P2093
P2860
P356
P1433
P1476
Antitumor efficacy of 34.5ENVE ...... 20"-expressing oncolytic virus
@en
P2093
Amy Haseley
Anna Bratasz
Balveen Kaur
E Antonio Chiocca
Ji Young Yoo
Jianying Zhang
Kimerly Powell
P2860
P304
P356
10.1038/MT.2011.208
P577
2011-10-25T00:00:00Z